Bluejay Diagnostics (NASDAQ:BJDX) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of Bluejay Diagnostics (NASDAQ:BJDX) from a hold rating to a sell rating in a research note issued to investors on Monday,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Bluejay Diagnostics presently has an average rating of “Sell”.

Bluejay Diagnostics Stock Down 4.1%

NASDAQ BJDX opened at $0.81 on Monday. Bluejay Diagnostics has a 52 week low of $0.80 and a 52 week high of $16.68. The business’s fifty day simple moving average is $1.03 and its 200-day simple moving average is $1.89. The firm has a market cap of $3.63 million, a PE ratio of -0.11 and a beta of 0.91.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($1.12) earnings per share for the quarter, beating the consensus estimate of ($3,520.00) by $3,518.88.

Insider Transactions at Bluejay Diagnostics

In other Bluejay Diagnostics news, major shareholder Financial Lp Hrt sold 34,938 shares of Bluejay Diagnostics stock in a transaction on Friday, July 10th. The stock was sold at an average price of $1.40, for a total value of $48,913.20. Following the sale, the insider owned 92,055 shares in the company, valued at $128,877. The trade was a 27.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 6.10% of the stock is currently owned by company insiders.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.